Biweekly DoceAqualip in mCRPC patients beyond 20 cycles: A case series

Introduction Docetaxel 75 mg/m2 every 3 weeks for up to 10 cycles is an accepted standard regimen in metastatic castration-resistant prostate cancer (mCRPC). We report our experience with >20 cycles of biweekly nanosomal docetaxel lipid suspension (NDLS) treatment in patients with mCRPC. Case reports Cases with long-term treatment of NDLS treatment in mCRPC patients were identified from the medical records of Jawaharlal Nehru Cancer Hospital & Research Centre Bhopal, India. A total of three cases with >20 cycles of NDLS are presented here. Management and outcomes Overall, the 3 patients received biweekly NDLS at a dose of 45 mg/m2 for 22, 36, and 40 cycles, respectively, except for one patient where NDLS was initiated at 50 mg/m2 and later reduced to 45 mg/m2. All the 3 patients reported prostate-specific antigen (PSA) response (>50% decline in PSA levels from baseline). The time to treatment failure (TTF) was 14.8, 18.2, and 20.6 months in these 3 patients, respectively. PSA nadir occurred after 14, 6 and 13 cycles, respectively. The OS was 21.6, 22.2 and 25.8 months, respectively. Anemia, lymphopenia, and neutropenia were the most common adverse events. NDLS treatment was overall well-tolerated without any new safety concerns. Conclusions Biweekly NDLS for >20 cycles was effective and well-tolerated in patients with mCRPC. NDLS can potentially be used for long-term management, which may be a requirement for most patients with mCRPC.

Download Full-text

Long-Term Management of Generalized Pustular Psoriasis with Infliximab: Case Series

Journal of Cutaneous Medicine and Surgery ◽

10.2310/7750.2008.07036 ◽

2008 ◽

Vol 12 (4) ◽

pp. 184-188 ◽

Cited By ~ 7

Author(s):

Shannon B. Routhouska ◽

Pranav B. Sheth ◽

Neil J. Korman

Keyword(s):

Case Reports ◽

Case Series ◽

Term Treatment ◽

Pustular Psoriasis ◽

Short Term Treatment ◽

Long Term Treatment ◽

Generalized Pustular Psoriasis ◽

Factor Α ◽

Term Management

Background: Infliximab, a tumor necrosis factor α antagonist, has recently been shown to be successful for the short-term treatment of generalized pustular psoriasis (GPP) in multiple case reports. Objective: The goal of this case series was to assess the efficacy of the longer-term management of GPP with infliximab. Methods: Three patients with severe GPP were followed to assess the efficacy of long-term treatment with infliximab. Results: Infliximab therapy was more efficacious with infusion every 6 to 8 weeks in combination with methotrexate. Conclusion: Infliximab may be efficacious for some patients for the long-term management of GPP. Maintaining a strict infliximab infusion schedule and concomitant methotrexate therapy may decrease infusion reactions and increase efficacy.

Download Full-text

The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia

European Psychiatry ◽

10.1016/s0924-9338(01)00583-1 ◽

2001 ◽

Vol 16 (5) ◽

pp. 307-312 ◽

Cited By ~ 10

Author(s):

J. Lynch ◽

J. Morrison ◽

N. Graves ◽

D. Meddis ◽

M.F. Drummond ◽

...

Keyword(s):

Health Economic ◽

Case Series ◽

Chronic Schizophrenia ◽

Term Treatment ◽

Revolving Door ◽

Psychotic Symptoms ◽

Open Label ◽

Economic Implications ◽

Long Term Treatment

SummaryThis retrospective, case series audit assessed the clinical and health-economic impact of long-term treatment with quetiapine (‘Seroquel’), a new atypical antipsychotic, in patients with chronic schizophrenia.The study design was of a case series format, comprising patients entered from one centre into the open-label extension of a multicentre 6-week efficacy study. Twenty-one patients (15 male, six female; mean age 39 years) were studied, of whom 17 (81%) had been rated as ‘partially responsive’ to previous antipsychotics. Data on hospitalisations and information on symptoms were collected retrospectively for the 12 months before quetiapine treatment was initiated and for the 12 months after.Quetiapine was effective in reducing psychotic symptoms with mean BPRS scores reducing significantly, from 38 to 21 (P < 0.005). Motor function was also significantly improved with mean Simpson scale scores reducing from 15 to 12 (P < 0.005). Average inpatient days were reduced by 11% in year two (97 compared with 109 days) while the overall costs of treatment, including drug costs, fell by 5% (I£20,843 to I£19,827).Four patients had been hospitalised for longer than 5 years before starting quetiapine; these chronically institutionalised patients remained in hospital, despite improved clinical outcomes (mean BPRS scores after treatment of 34, compared with 43 before), for the full 12 months of quetiapine treatment. Were the data from this audit to be re-analysed excluding these four patients then average inpatient days would have been reduced by 33% (45 to 30 days) and overall cost of treatment by 19% (I£8617 to I£7011).This audit suggests that treatment with quetiapine over this 1-year period was associated with both clinical improvements and a decreased usage of inpatient services. The reduction in hospitalisation costs would appear to compensate for the increased cost of drug treatment. Significantly, potential savings appear to be greatest for those patients with a ‘revolving door’ pattern of repeated readmission.

Download Full-text

Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/j.1468-3083.2004.00877.x ◽

2004 ◽

Vol 18 (2) ◽

pp. 169-172 ◽

Cited By ~ 11

Author(s):

M Garcia-Bustinduy ◽

M Escoda ◽

FJ Guimera ◽

M Saez ◽

S Dorta ◽

...

Keyword(s):

Cyclosporin A ◽

Plaque Psoriasis ◽

Case Series ◽

Term Treatment ◽

Chronic Plaque Psoriasis ◽

Retrospective Case ◽

Retrospective Case Series ◽

Long Term Treatment

Download Full-text

Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction

Hormone Molecular Biology and Clinical Investigation ◽

10.1515/hmbci-2017-0015 ◽

2017 ◽

Vol 30 (3) ◽

Cited By ~ 10

Author(s):

Abdulmaged Traish ◽

Karim Sultan Haider ◽

Gheorghe Doros ◽

Ahmad Haider

Keyword(s):

Blood Glucose ◽

Benign Prostatic Hyperplasia ◽

Specific Antigen ◽

Term Treatment ◽

Prostatic Hyperplasia ◽

Urinary Tract Symptoms ◽

Long Term Treatment

AbstractBackgroundDutasteride has been successfully used in treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). However, dutasteride inhibits 5α-reductase type 1 and type 2 enzymes and may compromises glucocorticoids and androgen metabolism and alters metabolic function resulting in undesirable metabolic and sexual adverse side effects.AimThe aim of this study was to investigate the long-term adverse effects of dutasteride therapy in men with BPH on: i) blood glucose, ii) glycated hemoglobin (HbAMethodsA retrospective registry study, with a cohort of 230 men aged between 47 and 68 years (mean 57.78 ± 4.81) were treated with dutasteride (0.5 mg/day) for LUTS, secondary to BPH. A second cohort of 230 men aged between 52 and 72 years (mean 62.62 ± 4.65) were treated with tamsulosin (0.4 mg). All men were followed up for 36–42 months. At intervals of 3–6 months, and at each visit, plasma glucose, HbAResultsLong-term treatment with dutasteride therapy is associated with significant improvements in LUTS, as assessed by reduction in prostate volume, IPSS and prostate specific antigen (PSA). Long-term dutasteride therapy, however, resulted in increased blood glucose, HbAConclusionOur findings suggest that long-term dutasteride therapy produces worsening of ED, reduced T levels and increased glucose, HbA

Download Full-text

Oxaliplatin for Metastatic Colon Cancer in a Patient with Renal Failure

Clinical medicine Oncology ◽

10.4137/cmo.s412 ◽

2008 ◽

Vol 2 ◽

pp. CMO.S412

Author(s):

Kenji Katsumata ◽

Tetsuo Sumi ◽

Tatehiko Wada ◽

Yasuharu Mori ◽

Masayuki Hisada ◽

...

Keyword(s):

Colorectal Cancer ◽

Renal Failure ◽

Term Treatment ◽

Pharmacokinetic Data ◽

Metastatic Colon Cancer ◽

Standard Regimen ◽

Long Term Treatment ◽

Before And After ◽

Cecal Cancer

Objective Oxaliplatin, a key part of the standard regimen for colorectal cancer in Western countries, has become available in Japan. In a hemodialysis patient with cecal cancer, we investigated the efficacy, safety, pharmacokinetics, and dialysability of oxaliplatin. Methods A 65-year-old man who had cecal cancer was treated with oxaliplatin (40 mg/m2) and l-leucovorin(l-LV) (200 mg/m2), which were administered simultaneously over 120 min via the side and main arms of a Y-tube, respectively. Then 5-FU (400 mg/m2) was administered rapidly via the side tube, followed by 5-FU (2,000 mg/m2) over 46 hours via the main tube. The patient had chronic renal failure due to diabetic nephropathy and hemodialysis was performed 3 times a week. Blood samples were collected from the dialyzer before and after each hemodialysis session to examine platinum clearance. Results The patient received 3 courses of oxaliplatin before he died of cancer. During hemodialysis, the platinum level fell from 0.32 μg/mL to 0.15 μg/mL. Conclusion Since patients with renal failure have various associated disorders and oxaliplatin has a long half-life, it is necessary to obtain more pharmacokinetic data to investigate its accumulation and dialysability during long-term treatment. Such data will assist in treating the rapidly increasing number of hemodialysis patients with colorectal cancer.

Download Full-text

Arthroscopic treatment of fragmented coronoid process with severe elbow incongruity

Veterinary and Comparative Orthopaedics and Traumatology ◽

10.3415/vcot-11-06-0087 ◽

2013 ◽

Vol 26 (01) ◽

pp. 27-33 ◽

Cited By ~ 7

Author(s):

E. de Bakker ◽

D. Van Vynckt ◽

E. Coppieters ◽

H. van Bree ◽

B. Van Ryssen ◽

...

Keyword(s):

Clinical Signs ◽

Case Series ◽

Term Treatment ◽

Coronoid Process ◽

Heavy Exercise ◽

Term Outcome ◽

Long Term Outcome ◽

Long Term Treatment

SummaryThe purpose of this study was to investigate the long-term treatment results of fragmented coronoid process (FCP) in joints with a radio-ulnar step greater than 3 mm. Treatment of these patients only consisted of fragment removal, without correction of the incongruity.The eight Bernese Mountain Dogs (11 joints) included in this study showed obvious clinical signs of elbow disease and were diagnosed with severe elbow incongruity and concomitant FCP in the time period from 1999–2003. At that time, elbow radiography, computed tomography, and arthroscopy were performed. The mean follow-up period was 5.6 years. The follow-up consisted of a telephone questionnaire combined with a clinical and radiographic re-evaluation at our clinic.The questionnaire revealed that all dogs were either free of lameness or only lame following heavy exercise. One dog sporadically required medication after heavy exercise. The owner satisfaction rate was 100%. The clinical re-evaluation did not reveal any signs of pain or lameness in all cases. Range-of- motion was decreased in nine of the 11 elbows. Radiographs revealed an increase in severity of osteoarthritis in every case.In this case series, arthroscopic fragment removal without treatment of incongruity was demonstrated to be a valuable treatment option and may provide a satisfactory long-term outcome.

Download Full-text